keynote-522: efs sensitivity & subgroup analyses
Published 2 years ago • 283 plays • Length 4:17Download video MP4
Download video MP3
Similar videos
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
5:01
keynote-522: final os findings of pembrolizumab and chemotherapy in tnbc
-
0:57
a post hoc analysis of adjuvant radiation therapy in the keynote-522 study
-
3:09
keynote-522: neoadjuvant and adjuvant pembrolizumab for early tnbc
-
4:20
keynote-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
13:03
early tnbc - pembrolizumab chemotherapy: pathologic complete response in key subgroups
-
9:43
week 16: 8th chemo done of taxol, carbo, & keytruda
-
12:30
immunotherapy treatments finished (keytruda) / triple negative breast cancer
-
1:08:58
tnbc current and emerging therapeutic strategies | 2023 best of breast conference
-
0:53
keynote-522 demonstrates potential for immunotherapy in triple-negative breast cancer
-
34:12
keynote-522
-
9:02
phase 3 keynote-522 results: pembro/chemo neoadjuvant, pembro adjuvant in early tnbc
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
0:50
update on keynote 522, the current standard of care for triple negative breast cancer.
-
32:04
educational sessions: "management of special subtypes of tnbc"
-
2:53
neoadjuvant chemoimmunotherapy: keynote-522, i-spy & more
-
2:25
new technology allows important discovery in triple negative breast cancer
-
4:50
triple negative breast cancer update: immunotherapy in stage 2-3 tnbc (keynote 522 update)
-
1:03
new directions in immunotherapy for improving outcomes in tnbc
-
13:44
first chemo treatment for tnbc. keynote 522